

TIME TO TEST:

BRCA in Breast Cancer virtual meeting

Time to Test: BRCA in Breast Cancer Virtual Meeting 23 & 24 November 2020

Dear partner,

We are pleased to formally invite you to attend the virtual **Time to Test: BRCA in Breast Cancer Meeting** which will take place on **23 & 24 November 2020**.

Faculty

- Dr Rebecca Dent, National Cancer Center, Singapore
- Dr Javier Cortes, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Prof Karen Gelmon, BC Cancer Agency, Vancouver, Canada

Please note you are invited to attend one session only, based on which date & time zone most suits your schedule and location.

During your registration please select one out of the two options below:

- **Monday 23 November 2020** – 16:30-18:00 (GMT) / 17:30-19:00 (CET) / 11:30-13:00 (EST) / **18:30-20:00 (Greek time)**
- OR
- **Tuesday 24 November 2020** – 09:00-10:30 (GMT) / 10:00-11:30 (CET) / 18:00-19:30 (JST)
- **18:30-20:00 (Greek time)**

The key objectives of the meeting are:

- Understand the relevance of biomarker testing for HER2-negative breast cancer, with a focus on germline BRCA mutation testing
- Have oversight on the considerations for BRCA testing in HER2-negative breast cancer, including different mechanisms for timely testing
- Consider the drivers and challenges for timely BRCA mutation testing, and how this may influence treatment decisions in these patients

Please note no honorarium / payment will be made for participation in this meeting.

PROGRAMME OUTLINE

| Time | Topic | Speaker |
|-------------------------------|---|---------------|
| 10 mins | Welcome and introductions | Javier Cortes |
| 15 mins <i>Run 25 mins</i> | Diagnostics in breast cancer: the current state of play <ul style="list-style-type: none"> • <i>Brief overview of different diagnostics for breast cancer (beyond HER2 / ER / PR)</i> | Rebecca Dent |

| | | |
|-------------------------------|---|---|
| 20 mins <i>Run 45 mins</i> | BRCA testing: where are we now? <ul style="list-style-type: none"> <i>Rationale for BRCA testing (eBC: surgery, platinum; aBC: PARPi, platinum)</i> <i>Overview of current situation – variation by geography</i> | Karen Gelmon |
| 15 mins <i>Run 60 mins</i> | Panel discussion <ul style="list-style-type: none"> <i>Timing of BRCA testing</i> <i>Actionability of results (e.g. decision vs. PARPi and IO)</i> <i>Challenges with different patient subgroups (e.g. TNBC vs. HR+)</i> | Javier Cortes, Karen Gelmon, Rebecca Dent, Nurse 1 TBC, Pathologist 1 TBC, Geneticist 1 TBC |
| 15 mins <i>Run 75 mins</i> | BRCA testing: practical implementation <ul style="list-style-type: none"> <i>Models for consenting and results to date</i> | Javier Cortes |
| 10 mins <i>Run 85 mins</i> | Panel discussion <ul style="list-style-type: none"> <i>Discussion on implementation</i> <i>View on broader positioning within diagnostic landscape</i> | Javier Cortes, Karen Gelmon, Rebecca Dent, Nurse 1 TBC, Pathologist 1 TBC, Geneticist 1 TBC |
| 5 mins <i>Run 90 mins</i> | Summary and close | Javier Cortes |

This promotional meeting has been organised and funded by AstraZeneca.

REGISTRATION

Please register your attendance via the link below by **Wednesday 18 November**.

[REGISTRATION LINK](#)

RECORDING

This meeting will be recorded, which will then be used to capture discussions and key findings. Audio recording will not be shared outside AstraZeneca.

JOINING INSTRUCTIONS

Once registered for the meeting, you will shortly receive a calendar invite reflecting your local time zone. Zoom instructions for joining the meeting will follow nearer to the meeting dates.

ASTRAZENECA GLOBAL CONGRESS & CONFERENCE TEAM CONTACTS

Please do not hesitate to contact us with any questions or queries.

Meeting Content / Program Queries

Rory Goodbody MPH PhD

Global Medical Affairs Leader

Email: rory.goodbody@astrazeneca.com

Logistics Queries

Hannah Caldwell & Paisley Williams

Delegate Management (registration)

Mobile: +44 (0) 7110 855 324 (Hannah)

Mobile: +44 (0) 7731 326 619 (Paisley)

Email: TimeToTest_2020@wrglive.com

Logistics Queries

Malin Flinck

Conference Project Manager, Global Congress & Conference Team

Email: Malin.Flinck@astrazeneca.com

We look forward to receiving your registration and your participation at this meeting.

Kind regards,

On behalf of the AstraZeneca Greece Dx team

Stamatelli Angeliki, PhD
Diagnostics Science Liaison



This message is sent from AstraZeneca.

AstraZeneca guarantees the quality and validity of the information provided in this newsletter, without prejudice to any technical or typographical errors that cannot be foreseen or have been unintentionally caused or due to interruptions to this site for reasons of force majeure.

We inform you that AstraZeneca, having obtained your prior relevant consent, shall keep record and process your personal data (full name, title, contact number, e-mail address) in order to send you medical information material and inform you about the scientific events organized by AstraZeneca. AstraZeneca handles the above personal data as well as any information you share in full respect and in accordance with the applicable regulatory and legal framework for the protection of personal data, always reserving your right to access the personal data retained by AstraZeneca.

Any information that you provide us, including adverse events or quality complaints, may be transferred to the regulatory authorities, our subsidiaries and / or business partners, with whom we are contractually linked. These parties may be situated in a different country than yours. For more information on AstraZeneca's privacy policy please enter here <https://www.globalprivacy.astrazeneca.com/gr>.

If you wish to be deleted from the list, please click here <https://mc-01-app-us.veevacrm.com/>. In case that this link is out of operation, you may send your request to the email address georgios.christias@astrazeneca.com with subject "Deletion from newsletter recipient list". Mr George Christias is AstraZeneca's authorized person to whom you may address in order to exercise your right to information, access and objection to the processing of your personal data (contact number 210-6871500, email address: georgios.christias@astrazeneca.com)

Finally, for the purposes of medical information, we inform you that you can either visit the AstraZeneca Greece Medical Information Department website: <https://medicalinformation.astrazeneca.gr/> or contact 0030 210-6871500

©2020 AstraZeneca. All rights reserved.